We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+3.27%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$7.23B
AUM Growth
+$298M
(+4.3%)
Cap. Flow
+$149M
Cap. Flow
% of AUM
2.07%
Top 10 Holdings %
Top 10 Hldgs %
15.39%
Holding
1,100
New
151
Increased
415
Reduced
333
Closed
164
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$40.6M |
| 2 |
Autodesk
ADSK
|
+$38.8M |
| 3 |
Intuit
INTU
|
+$37.1M |
| 4 |
Ecolab
ECL
|
+$35.6M |
| 5 |
Coca-Cola
KO
|
+$35.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$51.9M |
| 2 |
EOG Resources
EOG
|
+$33.8M |
| 3 |
DATA
Tableau Software, Inc.
DATA
|
+$32M |
| 4 |
Microsoft
MSFT
|
+$29.8M |
| 5 |
Ford
F
|
+$29.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.67% |
| 2 | Financials | 17.68% |
| 3 | Consumer Discretionary | 13.74% |
| 4 | Industrials | 11.53% |
| 5 | Healthcare | 11.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Estee Lauder
EL
$29B
| $8.5M | 0.12% |
+46,424
| New | +$7.93M |
|
227
Idexx Laboratories
IDXX
$42.9B
| $8.49M | 0.12% |
30,828
-35,275
| -53% | -$8.69M |
|
228
Southwest Gas
SWX
$6.74B
| $8.49M | 0.12% |
94,705
+57,961
| +158% | +$4.92M |
|
229
Avis
CAR
$5.63B
| $8.44M | 0.12% |
240,070
+26,500
| +12% | +$889K |
|
|
EQC
230
DELISTED
Equity Commonwealth
EQC
| $8.39M | 0.12% |
257,870
+38,450
| +18% | +$1.25M |
|
231
CF Industries
CF
$19.2B
| $8.36M | 0.12% |
179,024
+85,810
| +92% | +$3.72M |
|
232
Avista
AVA
$3.47B
| $8.36M | 0.12% |
187,363
+108,486
| +138% | +$4.62M |
|
|
LPT
233
DELISTED
Liberty Property Trust
LPT
| $8.3M | 0.11% |
165,934
+20,680
| +14% | +$1.01M |
|
234
Viatris
VTRS
$20.1B
| $8.3M | 0.11% |
435,990
+128,920
| +42% | +$2.85M |
|
235
Capital One
COF
$124B
| $8.29M | 0.11% |
91,377
-3,930
| -4% | -$351K |
|
|
HDS
236
DELISTED
HD Supply Holdings, Inc.
HDS
| $8.29M | 0.11% |
205,750
-12,400
| -6% | -$532K |
|
237
Maximus
MMS
$3.14B
| $8.25M | 0.11% |
113,685
-27,180
| -19% | -$1.97M |
|
238
Churchill Downs
CHDN
$6.03B
| $8.23M | 0.11% |
143,062
+95,862
| +203% | +$4.81M |
|
239
National Bank Holdings
NBHC
$1.93B
| $8.2M | 0.11% |
225,949
+5,360
| +2% | +$194K |
|
240
Progress Software
PRGS
$1.55B
| $8.18M | 0.11% |
187,470
-131,513
| -41% | -$5.7M |
|
241
Equinix
EQIX
$107B
| $8.08M | 0.11% |
16,014
-7,456
| -32% | -$3.58M |
|
242
Adtran
ADTN
$798M
| $8.02M | 0.11% |
526,094
+41,610
| +9% | +$664K |
|
|
PFPT
243
DELISTED
Proofpoint, Inc.
PFPT
| $8.02M | 0.11% |
66,704
+31,217
| +88% | +$3.68M |
|
244
Pacira BioSciences
PCRX
$1.02B
| $8.01M | 0.11% |
184,099
+13,660
| +8% | +$580K |
|
245
Par Pacific Holdings
PARR
$3.88B
| $7.91M | 0.11% |
385,454
+9,100
| +2% | +$177K |
|
246
Varex Imaging
VREX
$460M
| $7.86M | 0.11% |
256,518
+138,136
| +117% | +$4.21M |
|
247
Moog Inc Class A
MOG.A
$13B
| $7.82M | 0.11% |
83,481
-9,604
| -10% | -$856K |
|
|
CARB
248
DELISTED
Carbonite Inc
CARB
| $7.75M | 0.11% |
297,812
+7,020
| +2% | +$171K |
|
249
Rapid7
RPD
$634M
| $7.69M | 0.11% |
132,983
-29,797
| -18% | -$1.57M |
|
|
KRA
250
DELISTED
Kraton Corporation
KRA
| $7.66M | 0.11% |
246,654
-21,153
| -8% | -$639K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2019 Portfolio in Review
As of Q2 2019, Jacobs Levy Equity Management held 1,100 positions worth $7.23B, up 4.3% from $6.93B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Jacobs Levy Equity Management's Q2 2019 filing shows 151 new, 415 increased, 333 reduced and 164 closed positions. Its largest new stake was Biogen: 175,817 shares worth $41.1M. The largest sale was Allergan plc, an estimated $51.9M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
- Jacobs Levy Equity Management's largest Q2 2019 buy was Biogen: 175,817 shares worth $41.1M.
- Jacobs Levy Equity Management added most to Ecolab in Q2 2019, an estimated $35.6M increase.
- Jacobs Levy Equity Management's biggest Q2 2019 reduction was EOG Resources, cutting an estimated $33.8M.
- Jacobs Levy Equity Management fully exited Allergan plc in Q2 2019, selling an estimated $51.9M.
- Jacobs Levy Equity Management's ten largest holdings make up 15% of its $7.23B portfolio in Q2 2019.
- Jacobs Levy Equity Management opened 151 new positions and closed 164 in Q2 2019.
- Jacobs Levy Equity Management's portfolio value rose 4.3% quarter-over-quarter to $7.23B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2019, filed 13 Aug 2019.